Ayala Pharmaceuticals Inc.

1.07-0.1800-14.40%Vol 27.87K1Y Perf -88.38%
Jun 24th, 2022 16:00 DELAYED
BID1.03 ASK1.51
Open1.31 Previous Close1.25
Pre-Market- After-Market-
 - -  - -%
Target Price
13.38 
Analyst Rating
Strong Buy 1.13
Potential %
1.15K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     52.88
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★+     61.84
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
-1.17 
Earnings Rating
Market Cap15.07M 
Earnings Date
12th Aug 2022
Alpha-0.08 Standard Deviation0.20
Beta1.46 

Today's Price Range

1.071.31

52W Range

1.2314.95

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-15.08%
1 Month
-38.51%
3 Months
-73.97%
6 Months
-87.72%
1 Year
-88.38%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AYLA1.07-0.1800-14.40
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.71-0.667.04
Q04 2021-0.67-0.661.49
Q03 2021-0.76-0.6810.53
Q02 2021-0.63-0.75-19.05
Q01 2021-0.71-0.74-4.23
Q04 2020-0.58-0.73-25.86
Q03 2020-0.59-0.590.00
Q02 2020-0.53-0.74-39.62
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date12th Aug 2022
Estimated EPS Next Report-0.68
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume27.87K
Shares Outstanding14.09K
Shares Float5.45M
Trades Count87
Dollar Volume33.72K
Avg. Volume57.51K
Avg. Weekly Volume19.59K
Avg. Monthly Volume96.70K
Avg. Quarterly Volume56.25K

Ayala Pharmaceuticals Inc. (NASDAQ: AYLA) stock closed at 1.07 per share at the end of the most recent trading day (a -14.4% change compared to the prior day closing price) with a volume of 27.87K shares and market capitalization of 15.07M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 31 people. Ayala Pharmaceuticals Inc. CEO is Roni Mamluk.

The one-year performance of Ayala Pharmaceuticals Inc. stock is -88.38%, while year-to-date (YTD) performance is -87.43%. AYLA stock has a five-year performance of %. Its 52-week range is between 1.23 and 14.95, which gives AYLA stock a 52-week price range ratio of -1.17%

Ayala Pharmaceuticals Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 0.72, a price-to-sale (PS) ratio of 5.94, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -90.59%, a ROC of -103.29% and a ROE of -104.59%. The company’s profit margin is -%, its EBITDA margin is -1 331.40%, and its revenue ttm is $2.99 Million , which makes it $0.21 revenue per share.

Of the last four earnings reports from Ayala Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.68 for the next earnings report. Ayala Pharmaceuticals Inc.’s next earnings report date is 12th Aug 2022.

The consensus rating of Wall Street analysts for Ayala Pharmaceuticals Inc. is Strong Buy (1.13), with a target price of $13.38, which is +1 150.47% compared to the current price. The earnings rating for Ayala Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Ayala Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Ayala Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 31.41, ATR14 : 0.19, CCI20 : -137.11, Chaikin Money Flow : -0.23, MACD : -0.28, Money Flow Index : 45.98, ROC : -42.47, RSI : 24.44, STOCH (14,3) : 0.00, STOCH RSI : 0.00, UO : 19.05, Williams %R : -100.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Ayala Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (87.50 %)
7 (87.50 %)
7 (87.50 %)
Moderate Buy
1 (12.50 %)
1 (12.50 %)
1 (12.50 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.13
Strong Buy
1.13
Strong Buy
1.13

Ayala Pharmaceuticals Inc.

Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company's current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell specific leukemia.

CEO: Roni Mamluk

Telephone: +972 83731541

Address: Oppenheimer 4, Rehovot 7670104, , IL

Number of employees: 31

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

80%20%

Bearish Bullish

58%42%

Bearish Bullish

62%38%

TipRanks News for AYLA

News

Stocktwits